Johnson & Johnson (J&J) can now offer rheumatoid arthritis (RA) patients in the US an alternative to its subcutaneous version of Simponi after regulators approved the intravenous version Simponi Aria.
Janssen announced new Phase 3 findings from a study which showed treatment with the investigational intravenous (IV) therapy golimumab, a tumor necrosis factor (TNF) inhibitor, significantly inhibited ...
Simponi and Simponi Aria (golimumab) can cause mild to serious side effects. A more common side effect includes upper respiratory infection. If side effects from the drug become difficult to tolerate, ...
Recently reported results of a phase 3 study found that patients with psoriatic arthritis (PsA) who received intravenous golimumab (Simponi) had significantly greater improvements in the signs and ...
US regulators have expanded the scope of Janssen Biotech’s Simponi Aria to include the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). US regulators ...
What Is Simponi, and Why Does It Matter? The FDA has approved Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kilograms (33 pounds).
SIMPONI® Receives CHMP Positive Opinion For Treatment Of Polyarticular Juvenile Idiopathic Arthritis
LEIDEN, Netherlands, May 27, 2016 /PRNewswire/ -- Janssen Biologics B.V. (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
SIMPONI ARIA (golimumab) 50mg/4mL single-use vial Janssen Biotech announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the label for ...
BURLINGTON, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, between 2010 and 2013, ...
The US Food and Drug Administration (FDA) has approved golimumab (Simponi Aria, Janssen Biotech, Inc), intravenous (IV) formulation in combination with methotrexate, for the treatment of moderately to ...
Nr-axial SpA and ankylosing spondylitis (AS) come under the umbrella term of Axial Spondyloarthritis (axial SpA), [3] which is a painful and potentially progressive condition that mainly affects the ...
SIMPONI is approved in 70 countries for rheumatologic indications, including the European Union (EU), where SIMPONI received European Commission approval in October 2009 for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results